Cours Coeptis Therapeutics, Inc. OTC Markets
Actions
COEP
US19207C1045
Produits pharmaceutiques
CA 2022 | - | CA 2023 | - | Capitalisation | 26,74 M 24,22 M |
---|---|---|---|---|---|
Résultat net 2022 | -37 M -33,52 M | Résultat net 2023 | -21 M -19,02 M | VE / CA 2022 | - |
Trésorerie nette 2022 | 2,08 M 1,89 M | Trésorerie nette 2023 | 245 k 222 k | VE / CA 2023 | - |
PER 2022 |
-0,58
x | PER 2023 |
-0,95
x | Employés | 6 |
Rendement 2022 * |
-
| Rendement 2023 |
-
| Flottant | 67,46% |
Dirigeants | Titre | Age | Depuis |
---|---|---|---|
David Mehalick
CEO | Chief Executive Officer | 56 | 28/10/22 |
Brian Cogley
DFI | Director of Finance/CFO | 38 | 17/05/23 |
Daniel Yerace
COO | Chief Operating Officer | 41 | 28/10/22 |
Administrateurs | Titre | Age | Depuis |
---|---|---|---|
Director/Board Member | 62 | 28/10/22 | |
Director/Board Member | 55 | 28/10/22 | |
Christine Sheehy
CMP | Compliance Officer | 57 | 28/10/22 |
Varia. 1 janv. | Capi. | |
---|---|---|
+30,38% | 684 Md | |
+26,51% | 568 Md | |
-4,36% | 361 Md | |
+19,30% | 329 Md | |
+3,73% | 284 Md | |
+16,70% | 240 Md | |
+8,78% | 208 Md | |
-7,93% | 200 Md | |
+7,68% | 166 Md |